Quick search:
| Result | Content | Outlet | Published | Research |
|---|---|---|---|---|
| Result | Content | Outlet | Published | Research |
| 1 | Sarclisa-Containing Treatment Regimen Shows 'Remarkable' Results for Relapsed Myeloma | Curetoday.com | 2 days ago | |
| 2 | Kyprolis: Side Effects, Uses, Dosage, and More | Healthline | 2 months ago | |
| 3 | Kyprolis dosage: Form, strengths, how to use, and more | Medical News Today | 5 months ago | |
| 4 | Kyprolis: Side Effects and How to Manage Them | Healthline | 6 months ago | |
| 5 | FDA approves Kyprolis regimen for relapsed or refractory multiple myeloma | Healio | 6 months ago | |
| 6 | Xpovio-Kyprolis Combo Shows Good Response in Hard-to-treat Myeloma | Myeloma Research News | 3 months ago | |
| 7 | Elotuzumab Combination Disappoints in Newly Diagnosed Myeloma | Medpage Today | 7 days ago | |
| 8 | BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma | Business Wire | 10 months ago | |
| 9 | CRISPR Therapeutics (CRSP) Appoints Phuong Khanh Morrow as Chief Medical Officer | StreetInsider.com | 2 days ago | |
| 10 | Dara-KRd in NDMM: Results From the MASTER Study | Targeted Oncology | 10 days ago | |
| 11 | Kyprolis: Side effects, dosage, cost, use for multiple myeloma, and mo | Medical News Today | 2 years ago | |
| 12 | FDA approves Darzalex Faspro, Kyprolis, and Dexamethasone for multiple myeloma | The Cancer Letter | 6 months ago | |
| 13 | Kyprolis: Uses, Side Effects, Dosages, & Precautions | Verywell Health | 3 months ago | |
| 14 | LIGAND PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | Marketscreener.com | 9 days ago | |
| 15 | FDA Approves New Kyprolis Combination Regimen – PharmaLive | PharmaLive | 2 years ago | |
| 16 | Kyprolis Combo Shows Promise as Initial Therapy for Multiple Myeloma | Myeloma Research News | 3 years ago | |
| 17 | FDA Approves Darzalex + Kyprolis for Relapsed or Refractory MM | Clinical Oncology News | 2 years ago | |
| 18 | Kyprolis-Based Regimen Induces Similar Results as Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma | Curetoday.com | 11 months ago | |
| 19 | Once-a-week Kyprolis Effective for Untreated Multiple Myeloma Patients | Myeloma Research News | 3 years ago | |
| 20 | Recap: Treatment Options in Transplant-Eligible and -Ineligible Multiple Myeloma | Cancer Network | 4 days ago | |
| 21 | Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) Short Interest Update | Defense World | 15 hours ago | |
| 22 | [Special] Kyprolis vs Ninlaro. The winner in MM treatment market is … | KBR | 1 year ago | |
| 23 | FDA approves Sarclisa with Kyprolis for multiple myeloma | The Pharma Letter | 1 year ago | |
| 24 | FDA's Approval of Subcutaneous Darzalex-Based Regimen Adds Another 'Tool in the Toolbox' to Treat Pretreated Myeloma | Curetoday.com | 5 months ago | |
| 25 | KYPROLIS® (carfilzomib) Patents Upheld Against Generic Manufacturer | PR Newswire | 2 years ago | |
| 26 | FDA Approves Once-Weekly Kyprolis Regimen for Myeloma | Curetoday.com | 4 years ago | |
| 27 | Long-term Data Confirms Kyprolis Survival Benefit in Relapsed... | Myeloma Research News | 5 years ago | |
| 28 | Darzalex Faspro Combo Therapy for Myeloma Patients Approved by FDA | Myeloma Research News | 5 months ago | |
| 29 | Breckenridge Announces Approval of its ANDA for Carfilzomib Intravenous Powder (generic for Kyprolis®) | PR Newswire | 11 months ago | |
| 30 | Amgen's Kyprolis fails in first-line myeloma | BioPharma Dive | 6 years ago | |
| 31 | Carfilzomib (Kyprolis ): risk of reactivation of hepatitis B virus | GOV.UK | 2 years ago | |
| 32 | Can Amgen's new-and-improved Kyprolis kick-start myeloma sales? | FiercePharma | 4 years ago | |
| 33 | Kyprolis Duo Improves Survival in Multiple Myeloma | Curetoday.com | 5 years ago | |
| 34 | Kyprolis Combo Fails to Outperform Velcade for Multiple Myeloma... | Myeloma Research News | 6 years ago | |
| 35 | Myeloma Combo Reolysin-Kyprolis Shows Promising Responses in Trial | Myeloma Research News | 2 years ago | |
| 36 | Reolysin, Kyprolis Combo for Myeloma the Focus of Recent Expert Call | Myeloma Research News | 2 years ago | |
| 37 | Amgen's myeloma treatment Kyprolis gains NICE approval | pharmaphorum | 5 years ago | |
| 38 | Inside the Clinic: JTCC Experts Highlight Pivotal Ongoing Trials in Multiple Myeloma | OncLive | 2 months ago | |
| 39 | Preferences for Managing Relapsed Multiple Myeloma | Cancer Network | 3 months ago | |
| 40 | Subcutaneous Daratumumab Plus Kd Is a “Gamechanger” for Patients With Multiple Myeloma | OncLive | 4 months ago | |
| 41 | Longer survival seen with Amgen's Kyprolis vs Velcade in myeloma study | Reuters | 5 years ago | |
| 42 | Most influential people in biopharma, the scientists | FiercePharma | 9 days ago | |
| 43 | Sarclisa Triple Combo Prolongs Life Without Disease Progression in... | Myeloma Research News | 2 years ago | |
| 44 | SMC gives green light for Amgen's Kyprolis | PMLiVE | 5 years ago | |
| 45 | Velcade-Based Triplet Regimen 'Should Remain' Standard of Care in Newly Diagnosed Multiple Myeloma | Curetoday.com | 2 years ago | |
| 46 | FDA Approves Once-Weekly Dose of Kyprolis for R/R Multiple Myeloma | AJMC.com Managed Markets Network | 4 years ago | |
| 47 | Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma | PR Newswire | 7 years ago | |
| 48 | Progression-Free Survival and Minimal Residual Disease Negativity May Result From Combination Therapy in Newly Diagnosed Multiple Myeloma | Curetoday.com | 1 year ago | |
| 49 | KRd Plus Lenalidomide Maintenance Yielded Positive MRD- CRs and May Delay End-Organ Disease in High-Risk Smoldering Myeloma | Cancer Network | 7 months ago | |
| 50 | 20 Years of Advancements Brings a 'Luxury' of Treatment Options for Patients With Myeloma | Curetoday.com | 2 months ago | |
| 51 | New Drug Combination for Unresponsive Multiple Myeloma Needs a Closer Look | Curetoday.com | 6 years ago | |
| 52 | Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma | Cancer Network | 5 months ago | |
| 53 | FDA Approves Isatuximab Plus Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma | OncLive | 1 year ago | |
| 54 | Daratumumab-Led Quad Therapy Aids MRD Surveillance in MM | AJMC.com Managed Markets Network | 5 months ago | |
| 55 | Luciano Costa, MD, PhD, Discusses Topline Data Utilizing KRd in Newly Diagnosed Myeloma | Cancer Network | 8 months ago | |
| 56 | Myeloma Prevented With Kyroplis Combo, Stem Cell Transplant, Data Say | Myeloma Research News | 2 years ago | |
| 57 | $332.26 Million in Sales Expected for BeiGene, Ltd. (NASDAQ:BGNE) This Quarter | Defense World | 3 days ago | |
| 58 | Darzalex (daratumumab): Side effects, cost, dosage, and more | Medical News Today | 2 years ago | |
| 59 | Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting | Yahoo Finance | 2 months ago | |
| 60 | Luciano Costa, MD, PhD, Shares Key Takeaways From the MASTER Trial in Multiple Myeloma | Cancer Network | 7 months ago | |
| 61 | Myeloma Study Finds Pomalyst More Cost-Effective Than Two Rivals | Myeloma Research News | 5 years ago | |
| 62 | AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS | PR Newswire | 3 months ago | |
| 63 | Tweet Chat Recap: Evolving Options for Newly Diagnosed Multiple Myeloma | Targeted Oncology | 9 months ago | |
| 64 | Amgen Inc. (NASDAQ:AMGN) Plans Quarterly Dividend of $1.94 | Defense World | 5 days ago | |
| 65 | FDA Approval Insights: Isatuximab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | OncLive | 9 months ago | |
| 66 | Second indication of Sarclisa for relapsed MM approved by EC | The Pharma Letter | 1 year ago | |
| 67 | Daratumumab Plus KRd Regimen for Myeloma Results in Favorable MRD Negativity Rates | Cancer Network | 1 year ago | |
| 68 | Iberdomide Combination Shows Promise and Tolerability in Multiple Myeloma | OncLive | 8 months ago | |
| 69 | Part 1: Benefit Shown With Transplant and Combination Therapy in Multiple Myeloma | Targeted Oncology | 4 months ago | |
| 70 | Once-Weekly Carfilzomib Regimen Approved by the FDA for Myeloma | Targeted Oncology | 4 years ago | |
| 71 | Triplet Regimen Options Reviewed for Multiple Myeloma | Targeted Oncology | 10 months ago | |
| 72 | Combinations Offer Multiple Treatment Options in Relapsed/Refractory Multiple Myeloma | Targeted Oncology | 7 months ago | |
| 73 | Costa Reviews Regimens for Patients With Transplant-Eligible and Transplant-Ineligible NDMM | Targeted Oncology | 2 months ago | |
| 74 | Transplant-Ineligible Multiple Myeloma: Triplet vs Quadruplet Therapy | Cancer Network | 3 months ago | |
| 75 | Costa Breaks Down Treatment Options for Patients With Multiple Myeloma | Targeted Oncology | 6 months ago | |
| 76 | Part 1: Selecting Treatment Options for Relapsed/Refractory Multiple Myeloma | Targeted Oncology | 4 months ago | |
| 77 | New myeloma meds offer improvement, but are far too expensive: Report | FiercePharma | 6 years ago | |
| 78 | Why Amgen, Inc.'s Kyprolis FOCUS Failure Is a Big Deal | The Motley Fool | 8 years ago | |
| 79 | Frontline Use of Daratumumab-Based Regimens in Transplant-Ineligible MM | AJMC.com Managed Markets Network | 4 months ago | |
| 80 | Novel Agents Help Bridge Gaps in Care in Multiple Myeloma | OncLive | 5 months ago | |
| 81 | Dr. Hari on the Role of Carfilzomib, Pomalidomide, and Dexamethasone in R/R Myeloma | OncLive | 1 year ago | |
| 82 | Velcade (bortezomib): Side effects, uses, cost, and more | Medical News Today | 2 years ago | |
| 83 | Amgen 2021: Breakaway potential – PharmaLive | PharmaLive | 7 months ago | |
| 84 | Three-Drug Combination Improves Progression-Free Survival in Patients with Multiple Myeloma | Curetoday.com | 2 years ago | |
| 85 | Experimental Treatments for Myeloma | Myeloma Research News | 7 months ago | |
| 86 | HALOZYME THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | Marketscreener.com | 8 days ago | |
| 87 | Four-drug combo therapy shows benefit for newly-diagnosed myeloma patients | PharmaTimes | 10 months ago | |
| 88 | Selinexor Approved in China for Relapsed or Refractory Multiple Myeloma | OncLive | 5 months ago | |
| 89 | Fonseca on Findings for First- Vs Second-Line Daratumumab for Transplant-Ineligible Myeloma | Cancer Network | 4 months ago | |
| 90 | Promising Developments in Treating Multiple Myeloma Coming at This Year’s AACR Meeting | Baystreet.ca | 2 months ago | |
| 91 | Multiple myeloma relapse: Signs, diagnosis, and outlook | Medical News Today | 6 months ago | |
| 92 | Dr Joshua Richter Explains Importance of Cytogenetics in Multiple Myeloma | AJMC.com Managed Markets Network | 4 months ago | |
| 93 | Surgical Staging Affects Some QOL Scores in Early Breast Cancer | Cancer Therapy Advisor | 5 months ago | |
| 94 | Selinexor Combo Leads to Strong, Durable Responses in RRMM Patients | Myeloma Research News | 3 years ago | |
| 95 | New Analysis Confirms Carfilzomib Survival Benefit in Relapsed/Refractory Myeloma | OncLive | 4 years ago | |
| 96 | FDA gives full approval to Amgen blood cancer drug | Reuters | 6 years ago | |
| 97 | real-world data confirms that carfilzomib, lenalidomide, and dexamethasone are a safe and effective option for patients with relapsed or refractory multiple myeloma | AJMC.com Managed Markets Network | 1 year ago | |
| 98 | NICE rebuffs J&J's Darzalex price for newly diagnosed myeloma but leaves negotiation door open | FiercePharma | 9 months ago | |
| 99 | Sanofi (SNY), Blackstone Ink Deal for Subcutaneous Sarclisa | Nasdaq | 2 months ago | |
| 100 | FDA approves Onyx blood cancer drug Kyprolis | Fox News | 7 years ago |